Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa
SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtypes of Epidermolysis Bullosa MOUNT PLEASANT, S.C., Oct. 22, 2026 /PRNewswire/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare diseases,...
Ping An Unveils China’s First Brain Health Service Management Program, Focused on Alzheimer’s Prevention and Care
HONG KONG and SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- On 21 October, Ping An Insurance (Group) Company of China ("Ping An") unveiled China's first Brain Health Service Management Program at a seminar in Beijing on proactive Alzheimer's management and brain health services. At the event, Ping An and its health and senior-care flagship, Ping An Good Doctor (Stock...
HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor immunity Initial studies focus on gastric and breast cancers; expands to evaluate AST-301 and investigational PD-L1 cancer vaccines across multiple modalities Leverages FDA Orphan Drug Designations for both lead assets in gastric cancer to accelerate...
[China’s Voice] Preclinical Animal Study: Domestic Neurointerventional Robotic System PANVIS STAR® Completes Validation of Five Major Neurointerventional Procedures
SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Neurointerventional robots have long remained at the stage of "only being able to assist with angiography." Through close medical-engineering collaboration with Professor Jianmin Liu's team at Shanghai Changhai Hospital, Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. independently developed a new-generation vascular interventional surgical robot technology and product platform, PANVIS STAR®, for neurointerventional...
Rznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European Commission
SEONGNAM, South Korea, Oct. 22, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced today that the European Commission (EC) has granted Orphan Medicinal Product Designation to 'taspitimagene advec(RZ-001)', its RNA-editing gene therapy for the treatment of glioma. The designation follows...
Indegene Receives Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization
Indegene is recognized for combining domain-led AI, knowledge orchestration, and integrated execution to transform pharmaceutical commercialization workflows. SAN ANTONIO, Oct. 22, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Indegene has received the 2026 Global Enabling Technology Leadership Recognition in pharma AI-powered commercialization services for its outstanding achievements in AI-powered commercialization, workflow transformation, and customer value creation....
NUH WINS GOLD AT IHF AWARDS 2026 FOR GREEN OPERATING THEATRE PROGRAMME
NUH won Gold and received an Honourable Mention for its sustainability efforts at the International Hospital Federation Awards 2026, alongside presentations of its green surgical initiatives, digital health and organisational improvement initiatives at the World Hospital Congress. SINGAPORE, Oct. 22, 2026 /PRNewswire/ -- The National University Hospital (NUH) has won the Gold...
Taimei Technology and GreenLight Clinical Expand Strategic Partnership at AusBiotech 2026 to Pioneer AI-Native Trial Execution Across Asia-Pacific
GOLD COAST, Australia, Oct. 22, 2026 /PRNewswire/ -- Taimei Technology, a global provider of AI-powered clinical development platforms, and GreenLight Clinical (GLC), a physician-led contract research organization (CRO), today announced an expanded strategic partnership at AusBiotech 2026. Evolving from a targeted software engagement into an enterprise-wide alliance, the agreement equips GLC to scale trial delivery across the Asia-Pacific...
Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids
DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced today that its THERAKOS™ CELLEX™ Photopheresis System has received certification under the EU MDR for an expanded indication. The system is now indicated in Europe for the...
Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer...
